Analyst Update: Oshkosh, Eagle Pharma, Fortinet

Analysts adjusted their ratings on Oshkosh Corporation (NYSE:OSK), Eagle Pharmaceuticals Inc (NASDAQ:EGRX), and Fortinet Inc (NASDAQ:FTNT)

Jun 16, 2015 at 1:48 PM
facebook twitter linkedin

Analysts are weighing in on industrial equipment manufacturer Oshkosh Corporation (NYSE:OSK), drugmaker Eagle Pharmaceuticals Inc (NASDAQ:EGRX), and cybersecurity specialist Fortinet Inc (NASDAQ:FTNT). Here's a quick roundup of today's brokerage notes on OSK, EGRX, and FTNT.

  • A downwardly revised full-year profit forecast prompted J.P. Morgan Securities to cut its price target on OSK to $44 from $46. As such, the shares are down 8.1% today at $46.22 -- and back in the red on a year-to-date basis. Considering the stock was staring at a nearly 6% 52-week deficit heading into today's session, option traders have been skeptical of OSK. In fact, the security's Schaeffer's put/call open interest ratio (SOIR) of 4.13 rests at an annual peak, meaning short-term speculators are more put-heavy now than they've been at any other point during the past year. Today, puts are trading at three times the average intraday pace, with buy-to-open activity detected at Oshkosh Corporation's July 45 strike.

  • Unlike fellow drugmaker Avalanche Biotechnologies Inc (NASDAQ:AAVL), EGRX is having a great day. The stock hit a record high of $82.86 earlier -- and was last seen up 5.1% at $80.91 -- after Cantor Fitzgerald boosted its price target on the shares to $95 from $65. Specifically, the brokerage firm said it expects "less near-term generic competition to the company's 50 mL form of Treanda following a favorable Markman decision in Teva's generic litigation." Longer term, the shares have surged more than fivefold in 2015 -- and an extended rise could prompt a batch of bullish brokerage initiations or another round of price-target hikes. In fact, just three analysts follow the shares (each of which maintain a "strong buy"), and the average 12-month price target of $76.33 stands at a discount to Eagle Pharmaceuticals Inc's present price.

  • Cybersecurity stocks have been on fire recently, and today, it's FTNT's turn in the spotlight. The equity topped out at an all-time peak of $42.35 not that long ago, after Oppenheimer raised its price target to $46 from $39 and upped its second-quarter revenue forecast, saying "FTNT's business is tracking ahead of guidance." More recently, the stock was up 2.9% at $42.27 -- extending its year-to-date lead to an impressive 38%. On the sentiment front, most analysts are already on the bullish bandwagon, with two-thirds of those covering the shares maintaining a "buy" or better rating. However, with Fortinet Inc's consensus 12-month price target of $42.12 sitting below current trading levels, additional upwardly revised price targets could be on the horizon. Looking ahead, the company will host its annual shareholder meeting on Friday.

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners